Cervical cancer screening could be less frequent, start later

October 17, 2016
High grade dysplasia (carcinoma in situ) in the uterine cervix. The abnormal epithelium is extending into a mucus gland to the left of centre. This disease can progress to invasive cancer (squamous cell carcinoma) of the cervix. Credit: Haymanj/public domain

Women may only need cervical cancer screening every 5-10 years—instead of every three years, as currently recommended—and may be able to start the screenings later in life, according to a new study from Harvard T.H. Chan School of Public Health.

The researchers found that less-intensive screening is needed among women who have been vaccinated against human papillomavirus (HPV), which causes almost all cases of cervical cancer, because the risk of these women developing cervical cancer is quite low.

The study will appear October 17, 2016, in the Journal of the National Cancer Institute (JNCI).

"This analysis enabled us to examine what would happen if we shifted from the current way we screen for cervical cancer—essentially, recommending the same type of screening for all women—to screening that takes into account whether women have been vaccinated against HPV and therefore face a substantially lower risk of cervical cancer," said Jane Kim, professor of health decision science at Harvard Chan School. "We found that continuing intensive screening among HPV-vaccinated women yields excessive costs and harms with little to no health benefit."

Since 2012, major guideline-making organizations have recommended that all women in the U.S. be screened for cervical cancer every three years beginning at age 21 with a Pap test (which checks for abnormal cells in the cervix), with the option of switching to a combination of Pap test and HPV testing (known as "cotesting") every five years beginning at age 30. However, current U.S. guidelines don't differentiate screening recommendations based on a woman's HPV vaccination status.

The Harvard Chan researchers developed a disease simulation model to estimate the risks and benefits of various screening protocols. Their model projected the health and economic effects of three different types of HPV vaccines that are currently approved for use, two of which have been available since 2006. The goal was to pinpoint screening strategies that would provide the biggest in the most cost-effective way.

According to the model, women with the lowest risk of cervical cancer—those vaccinated with the new "nonavalent" HPV vaccine (HPV-9), which targets seven types of HPV that cause nearly 90% of all cervical cancers—would only need screening four times in their life, every 10 years, starting at age 30 or 35. Women vaccinated with earlier versions of the HPV vaccine—the bivalent and quadrivalent vaccines (HPV-2 and HPV-4), which target two HPV types that cause roughly 70% of cervical cancers—would need screening every five years starting at age 25 or 30.

The researchers also found that screening with HPV testing alone would provide similar health benefits and value as a Pap test or cotesting, because the HPV test is highly sensitive and can more efficiently identify women who are likely to develop .

One limitation of the study is that it modeled scenarios in which women are fully vaccinated in pre-adolescence (as recommended) and fully compliant with screening protocols. The researchers noted that future studies should take into account actual vaccination uptake rates in the population and data on screening compliance in vaccinated women as these data become available over time.

Explore further: More than two-thirds of cervical cancer deaths prevented by screening

More information: "Optimal cervical cancer screening in women vaccinated against human papillomavirus," Jane J. Kim, Emily A. Burger, Stephen Sy, Nicole G. Campos, Journal of the National Cancer Institute, October 17, 2016, DOI: 10.1093/jnci/djw216

Related Stories

More than two-thirds of cervical cancer deaths prevented by screening

September 19, 2016
Cervical screening prevents 70 per cent of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83 per cent, according to research led by Queen Mary University of London (QMUL).

HPV vaccine reduced cervical abnormalities in young women

July 4, 2016
Young women who received the human papillomavirus (HPV) vaccine through a school-based program had fewer cervical cell anomalies when screened for cervical cancer, found a new study in CMAJ (Canadian Medical Association Journal).

Low incidence of cervical cancer, CIN3+ for HPV-negative women

October 7, 2016
(HealthDay)—Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+), which supports an extension of the cervical screening ...

ACOG: New recommendations for cervical cancer screening

December 23, 2015
(HealthDay)—In a practice bulletin published in the January issue of Obstetrics & Gynecology, new recommendations are presented for cervical cancer screening and prevention.

What's the best test for cervical cancer? Pap, HPV or both?

June 9, 2014
Should U.S. women be screened for cervical cancer with Pap tests, HPV tests or both? According to researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) while the merits of screening ...

Routine screenings prevent cervical cancer in elderly women

July 7, 2016
A new study from the University of Illinois confirms a link between routine Pap smear screenings and a lower risk of developing cervical cancer in women over age 65. However, most American health guidelines discourage women ...

Recommended for you

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.